Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Journal Volume
29
Journal Issue
10
Date Issued
2023-05-15
Author(s)
Liam, Chong Kin
Ahmad, Azura Rozila
Hsia, Te-Chun
Zhou, Jianying
Kim, Dong-Wan
Soo, Ross Andrew
Cheng, Ying
Lu, Shun
Shin, Sang Won
Zhang, Yiping
Zhao, Jun
Berghoff, Karin
Bruns, Rolf
Johne, Andreas
Wu, Yi-Long
Abstract
The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021).
Type
journal article